Sinoway Industrial Co., Ltd.

Linagliptin 668270-12-0 Linagliptin 668270-12-0

Linagliptin 668270-12-0
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic information of Linagliptin:

Name

Linagliptin

Alias

8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione

CAS NO.

668270-12-0

Molecular Formula

C25H28N8O2

Molecular Weight

472.54

Grade Standard

Medicine grade  / 99% min / GMP application / PMDA / DMF

Package Size

25kg/drum

Storage:

Keep in a well-closed container, protected from light and stored at a temperature of 2 to 8


Use of Linagliptin:

Linagliptin is used to control of blood glucose levels in people with type 2 diabetes by combining diet and exercise. Linagliptin controls glycemic in patients by inhibiting dipeptidyl peptidase-4 (DPP-4).

Compared with other DPP-4 inhibitors, the main advantages of linagliptin are: excellent renal safety and effective reduction of glycated hemoglobin. Lilacitin is mainly excreted in the form of a prototype, and after oral administration, the amount of renal excretion is only 5% of the dose, and even if administered intravenously, only 30.8% is excreted by the kidney, so the patient receiving the treatment does not need Regular examination of liver and kidney function and dose adjustment, all patients can be fixed doses, easy to prescribe.

COA of Linagliptin:

Items

 

Specification

 

Result

 

Assay

 

≥98.5%

 

99.77%

 

Appearance

 

White to light yellow powder

 

Light yellow powder

Loss on drying

≤0.5%

0.38%

Residue on drying

≤0.1%

0.07%

Single impurity

≤0.5%

0.08%

Total impurity

≤1.5%

0.23%



  • Galantamine Hydrobromide 1953-04-4
    Basic information of Galantamine Hydrobromide:NameGalantamine HydrobromideAliasGALANTHAMIDE HYDROBROMIDE;GALANTHAMINE HBR;galanthamine hydrobromide from lycoris sp.;Galanthamine Hydrobromide Injection... Galantamine Hydrobromide 1953-04-4
  • Febantel 58306-30-2
    Basic information of FebantelNameFebantelAliasmethyl N-[N-[2-[(2-methoxyacetyl)amino]-4-phenylsulfanyl-phenyl]-N'-methoxycarbonyl-carbamimidoyl]carbamateCAS NO.58306-30-2Molecular Formula C20H22N4O6SM... Febantel 58306-30-2
  • Entecavir 142217-69-4
    Basic information of EntecavirNameEntecavirAlias ETVCAS NO.142217-69-4Molecular FormulaC12H15N5O3Molecular Weight277.283Quality Standard96% minGrade StandardFood grade, Medicine gradePackage Size25kg/... Entecavir 142217-69-4
  • Penciclovir 39809-25-1
    Basic information.CAS NO.: 39809-25-1 Assay: 99.0% up Other Names: 2-Amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-oneDocuments: GMP Molecular Formula: C10H15N5O3Molecular Weight: 253.... Penciclovir 39809-25-1

MORE_DETAIL Linagliptin 668270-12-0

Basic information of Linagliptin:

Name

Linagliptin

Alias

8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione

CAS NO.

668270-12-0

Molecular Formula

C25H28N8O2

Molecular Weight

472.54

Grade Standard

Medicine grade  / 99% min / GMP application / PMDA / DMF

Package Size

25kg/drum

Storage:

Keep in a well-closed container, protected from light and stored at a temperature of 2 to 8


Use of Linagliptin:

Linagliptin is used to control of blood glucose levels in people with type 2 diabetes by combining diet and exercise. Linagliptin controls glycemic in patients by inhibiting dipeptidyl peptidase-4 (DPP-4).

Compared with other DPP-4 inhibitors, the main advantages of linagliptin are: excellent renal safety and effective reduction of glycated hemoglobin. Lilacitin is mainly excreted in the form of a prototype, and after oral administration, the amount of renal excretion is only 5% of the dose, and even if administered intravenously, only 30.8% is excreted by the kidney, so the patient receiving the treatment does not need Regular examination of liver and kidney function and dose adjustment, all patients can be fixed doses, easy to prescribe.

COA of Linagliptin:

Items

 

Specification

 

Result

 

Assay

 

≥98.5%

 

99.77%

 

Appearance

 

White to light yellow powder

 

Light yellow powder

Loss on drying

≤0.5%

0.38%

Residue on drying

≤0.1%

0.07%

Single impurity

≤0.5%

0.08%

Total impurity

≤1.5%

0.23%


Leave a Message Email Us

We will contact you within 24 hours.

  • TEL:+86-0592-5853819
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//